-
Something wrong with this record ?
Clostridioides difficile infections were predominantly driven by fluoroquinolone-resistant Clostridioides difficile ribotypes 176 and 001 in Slovakia in 2018-2019
A. Plankaova, M. Brajerova, V. Capek, G. Balikova Novotna, P. Kinross, J. Skalova, A. Soltesova, P. Drevinek, M. Krutova
Language English Country Netherlands
Document type Journal Article
- MeSH
- Anti-Bacterial Agents pharmacology therapeutic use MeSH
- Clostridioides difficile * genetics MeSH
- Clostridioides genetics MeSH
- Fluoroquinolones pharmacology MeSH
- Clostridium Infections * epidemiology drug therapy MeSH
- Humans MeSH
- Linezolid MeSH
- Macrolides MeSH
- Microbial Sensitivity Tests MeSH
- Multilocus Sequence Typing MeSH
- Ribotyping MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Slovakia MeSH
AIM: To investigate the epidemiology of Clostridioides difficile infection (CDI) in Slovakian hospitals after the emergence of ribotype 176 (027-like) in 2016. METHODS: Between 2018 and 2019, European Centre for Disease Control and Prevention CDI surveillance protocol v2.3 was applied to 14 hospitals, with additional data collected on recent antimicrobial use and the characterization of C. difficile isolates. RESULTS: The mean hospital incidence of CDI was 4.1 cases per 10,000 patient bed-days. One hundred and five (27.6%) in-hospital deaths were reported among the 381 cases. Antimicrobial treatment within the previous 4 weeks was recorded in 90.5% (333/368) of cases. Ribotype (RT)176 was detected in 50% (n=185/370, 14 hospitals) and RT001 was detected in 34.6% (n=128/370,13/14 hospitals) of cases with RT data. Overall, 86% (n=318/370) of isolates were resistant to moxifloxacin by Thr82Ile in GyrA (99.7%). Multi-locus variable tandem repeat analysis showed clonal relatedness of predominant RTs within and between hospitals. Seven of 14 sequenced RT176 isolates and five of 13 RT001 isolates showed between zero and three allelic differences by whole-genome multi-locus sequence typing. The majority of sequenced isolates (24/27) carried the erm(B) gene and 16/27 also carried the aac(6')-aph(2'') gene with the corresponding antimicrobial susceptibility phenotypes. Nine RT176 strains carried the cfr(E)gene and one RT001 strain carried the cfr(C) gene, but without linezolid resistance. CONCLUSIONS: The newly-predominant RT176 and endemic RT001 are driving the epidemiology of CDI in Slovakia. In addition to fluoroquinolones, the use of macrolide-lincosamide-streptogramin B antibiotics can represent another driving force for the spread of these epidemic lineages. In C. difficile, linezolid resistance should be confirmed phenotypically in strains with detected cfr gene(s).
Bioinformatics Centre 2nd Faculty of Medicine Charles University Prague Czech Republic
Department of Clinical Microbiology Unilabs Inc Roznava Slovakia
Institute of Microbiology The Czech Academy of Sciences BIOCEV Vestec Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23010913
- 003
- CZ-PrNML
- 005
- 20230801132707.0
- 007
- ta
- 008
- 230718s2023 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ijantimicag.2023.106824 $2 doi
- 035 __
- $a (PubMed)37116667
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Plankaova, Adriana $u Department of Clinical Microbiology, Unilabs Inc., Roznava, Slovakia
- 245 10
- $a Clostridioides difficile infections were predominantly driven by fluoroquinolone-resistant Clostridioides difficile ribotypes 176 and 001 in Slovakia in 2018-2019 / $c A. Plankaova, M. Brajerova, V. Capek, G. Balikova Novotna, P. Kinross, J. Skalova, A. Soltesova, P. Drevinek, M. Krutova
- 520 9_
- $a AIM: To investigate the epidemiology of Clostridioides difficile infection (CDI) in Slovakian hospitals after the emergence of ribotype 176 (027-like) in 2016. METHODS: Between 2018 and 2019, European Centre for Disease Control and Prevention CDI surveillance protocol v2.3 was applied to 14 hospitals, with additional data collected on recent antimicrobial use and the characterization of C. difficile isolates. RESULTS: The mean hospital incidence of CDI was 4.1 cases per 10,000 patient bed-days. One hundred and five (27.6%) in-hospital deaths were reported among the 381 cases. Antimicrobial treatment within the previous 4 weeks was recorded in 90.5% (333/368) of cases. Ribotype (RT)176 was detected in 50% (n=185/370, 14 hospitals) and RT001 was detected in 34.6% (n=128/370,13/14 hospitals) of cases with RT data. Overall, 86% (n=318/370) of isolates were resistant to moxifloxacin by Thr82Ile in GyrA (99.7%). Multi-locus variable tandem repeat analysis showed clonal relatedness of predominant RTs within and between hospitals. Seven of 14 sequenced RT176 isolates and five of 13 RT001 isolates showed between zero and three allelic differences by whole-genome multi-locus sequence typing. The majority of sequenced isolates (24/27) carried the erm(B) gene and 16/27 also carried the aac(6')-aph(2'') gene with the corresponding antimicrobial susceptibility phenotypes. Nine RT176 strains carried the cfr(E)gene and one RT001 strain carried the cfr(C) gene, but without linezolid resistance. CONCLUSIONS: The newly-predominant RT176 and endemic RT001 are driving the epidemiology of CDI in Slovakia. In addition to fluoroquinolones, the use of macrolide-lincosamide-streptogramin B antibiotics can represent another driving force for the spread of these epidemic lineages. In C. difficile, linezolid resistance should be confirmed phenotypically in strains with detected cfr gene(s).
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a fluorochinolony $x farmakologie $7 D024841
- 650 12
- $a Clostridioides difficile $x genetika $7 D016360
- 650 _2
- $a ribotypizace $7 D021521
- 650 _2
- $a Clostridioides $x genetika $7 D000082682
- 650 _2
- $a linezolid $7 D000069349
- 650 _2
- $a multilokusová sekvenční typizace $7 D058885
- 650 _2
- $a antibakteriální látky $x farmakologie $x terapeutické užití $7 D000900
- 650 12
- $a klostridiové infekce $x epidemiologie $x farmakoterapie $7 D003015
- 650 _2
- $a makrolidy $7 D018942
- 650 _2
- $a mikrobiální testy citlivosti $7 D008826
- 651 _2
- $a Slovenská republika $x epidemiologie $7 D018154
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Brajerova, Marie $u Department of Medical Microbiology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Capek, Vaclav $u Bioinformatics Centre, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Balikova Novotna, Gabriela $u Institute of Microbiology, The Czech Academy of Sciences, BIOCEV, Vestec, Czech Republic
- 700 1_
- $a Kinross, Pete $u Department of Medical Microbiology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Skalova, Jana $u Department of Clinical Microbiology, Unilabs Inc., Roznava, Slovakia
- 700 1_
- $a Soltesova, Anna $u Department of Clinical Microbiology, Unilabs Inc., Roznava, Slovakia
- 700 1_
- $a Drevinek, Pavel $u Department of Medical Microbiology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Krutova, Marcela $u Department of Medical Microbiology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic. Electronic address: marcela.krutova@lfmotol.cuni.cz
- 773 0_
- $w MED00005050 $t International journal of antimicrobial agents $x 1872-7913 $g Roč. 62, č. 1 (2023), s. 106824
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37116667 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132704 $b ABA008
- 999 __
- $a ok $b bmc $g 1963372 $s 1197178
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 62 $c 1 $d 106824 $e 20230426 $i 1872-7913 $m International journal of antimicrobial agents $n Int J Antimicrob Agents $x MED00005050
- LZP __
- $a Pubmed-20230718